Vaccine Development [Working Title]最新文献

筛选

英文中文

Eg95: A Vaccine against Cystic Echinococcosis Eg95:一种囊性包虫病疫苗

Vaccine Development [Working Title] Pub Date : 2022-02-07 DOI: 10.5772/intechopen.101695

Arun K. De, T. Sujatha, J. Sunder, P. Bala, P. Perumal, D. Bhattacharya, Eaknath Bhanudasrao Chakurkar

{"title":"Eg95: A Vaccine against Cystic Echinococcosis","authors":"Arun K. De, T. Sujatha, J. Sunder, P. Bala, P. Perumal, D. Bhattacharya, Eaknath Bhanudasrao Chakurkar","doi":"10.5772/intechopen.101695","DOIUrl":"https://doi.org/10.5772/intechopen.101695","url":null,"abstract":"Hydatidosis or cystic echinococcosis (CE) is caused by the larval stage of the tapeworm Echinococcus granulosus. This parasite is cosmopolitan in distribution and causes significant economic losses to the meat industry, mainly due to condemnation of edible offal. Echinococcosis treatment in human is very expensive as it requires extensive surgery or prolonged chemotherapy or use of both. In Asia and Africa, the vulnerable population of developing the disease is around 50 million. Office International des Epizooties (OIE) has recognized CE as a multi species disease. The parasite has acquired the capability to survive long time within the host due to a specific mechanism to evade the host immune system. A specific class of proteins known as secreted and membrane bound (S/M) proteins play key roles in the evasion mechanism. A total of 12 S/M proteins have been reported as immunodiagnostic and immunoprophylactic agents. Of these, Eg95 is a candidate antigen used for immunization of animals. Literature suggests that, Eg95 is a multi-gene family (Eg95-1 to Eg95-7) and exists in seven different isoforms. This chapter will describe minutely efficacy of Eg95 as a vaccine candidate based on animal trial and potentiality of other S/M proteins as immunodiagnostic antigen and immune evasion.","PeriodicalId":234164,"journal":{"name":"Vaccine Development [Working Title]","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115136691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Next-Generation Vaccines Based on Self-Amplifying RNA 基于自我扩增RNA的新一代疫苗

Vaccine Development [Working Title] Pub Date : 2021-12-14 DOI: 10.5772/intechopen.101467

Fatemeh Nafian, Simin Nafian, Ghazal Soleymani, Zahra Pourmanouchehri, Mahnaz Kiyanjam, Sharareh Berenji Jalaei, Hanie Jeyroudi, Sayed Mohammad Mohammdi

{"title":"Next-Generation Vaccines Based on Self-Amplifying RNA","authors":"Fatemeh Nafian, Simin Nafian, Ghazal Soleymani, Zahra Pourmanouchehri, Mahnaz Kiyanjam, Sharareh Berenji Jalaei, Hanie Jeyroudi, Sayed Mohammad Mohammdi","doi":"10.5772/intechopen.101467","DOIUrl":"https://doi.org/10.5772/intechopen.101467","url":null,"abstract":"Recently, nucleic acid-based RNA and DNA vaccines have represented a better solution to avoid infectious diseases than “traditional” live and non-live vaccines. Synthetic RNA and DNA molecules allow scalable, rapid, and cell-free production of vaccines in response to an emerging disease such as the current COVID-19 pandemic. The development process begins with laboratory transcription of sequences encoding antigens, which are then formulated for delivery. The various potent of RNA over live and inactivated viruses are proven by advances in delivery approaches. These vaccines contain no infectious elements nor the risk of stable integration with the host cell genome compared to conventional vaccines. Conventional mRNA-based vaccines transfer genes of interest (GOI) of attenuated mRNA viruses to individual host cells. Synthetic mRNA in liposomes forms a modern, refined sample, resulting in a safer version of live attenuated RNA viruses. Self-amplifying RNA (saRNA) is a replicating version of mRNA-based vaccines that encode both (GOI) and viral replication machinery. saRNA is required at lower doses than conventional mRNA, which may improve immunization. Here we provide an overview of current mRNA vaccine approaches, summarize highlight challenges and recent successes, and offer perspectives on the future of mRNA vaccines.","PeriodicalId":234164,"journal":{"name":"Vaccine Development [Working Title]","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130017560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0